COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma (MM), the congress brought together leading experts from around the world to discuss the latest advances in research, novel therapies, and patient care.
ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

Trastuzumab deruxtecan (T-DXd) has dramatically reshaped the treatment landscape for advanced HER2-positive breast cancer because of its outstanding efficacy. It is now considered the standard second-line treatment for HER2-positive advanced breast cancer and has also demonstrated remarkable activity in both the first-line metastatic and early breast cancer settings.
CSCO BC 10th Anniversary Tribute | Professor Zefei Jiang: A Decade of Progress — CSCO BC Leading China’s Breast Cancer Field Toward a New Global Era

CSCO BC 10th Anniversary Tribute | Professor Zefei Jiang: A Decade of Progress — CSCO BC Leading China’s Breast Cancer Field Toward a New Global Era

Along the long journey of breast cancer prevention and treatment, the successful convening of the 2026 National Breast Cancer Conference stands as a shining milestone. Even more significant is the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC). Over the past decade, CSCO BC has grown from its inception into a major driving force in China’s breast cancer field, achieving remarkable progress in clinical research, guideline development, promotion of standardized care, and international academic collaboration.
AOT 2026 | Professor Dong-won Baek: Infection Risk and Management Strategies for Patients With GVHD Following Hematopoietic Stem Cell Transplantation

AOT 2026 | Professor Dong-won Baek: Infection Risk and Management Strategies for Patients With GVHD Following Hematopoietic Stem Cell Transplantation

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading experts in hematology from around the world to discuss cutting-edge innovations and future trends in hematopoietic stem cell transplantation.
Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

On February 6, 2026, Nature Communications published online a study led by Academician Xu Binghe from the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences. The single-arm Phase Ib trial evaluated the efficacy and safety of the novel oral pan-AKT inhibitor afuresertib combined with fulvestrant in previously treated patients with HR-positive/HER2-negative advanced breast cancer.
CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

With the continuous emergence of novel therapies and landmark clinical evidence, the treatment landscape of urothelial carcinoma is undergoing profound transformation. Ahead of the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, Oncology Frontier – UroStream presents a special series of expert previews on major genitourinary oncology guidelines. In this issue, Professor Cuijian Zhang from Peking University First Hospital, Secretary of the CSCO Urothelial Carcinoma Expert Committee, discusses the evolution of the CSCO urothelial carcinoma guidelines, highlights potential updates in the upcoming edition, and shares insights into the clinical significance of emerging evidence and future directions in the field. His perspectives offer clinicians an early look at evolving treatment paradigms aimed at improving outcomes for Chinese patients.
International Perspectives from EBMT | Professor Florent Malard: New Frontiers in Microbiome-Based Therapy for the Treatment and Prevention of Graft-versus-Host Disease

International Perspectives from EBMT | Professor Florent Malard: New Frontiers in Microbiome-Based Therapy for the Treatment and Prevention of Graft-versus-Host Disease

Graft-versus-host disease (GVHD) remains one of the most severe complications following hematopoietic stem cell transplantation. Among its manifestations, acute gastrointestinal GVHD is particularly challenging to manage. Despite standard therapies, a substantial proportion of patients fail treatment, and no approved therapeutic options currently exist for those with refractory disease, representing a major unmet medical need.
Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

To further promote the expansion, equitable distribution, and accessibility of high-quality cancer care resources, and to enhance the academic and clinical capabilities of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.
Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years of transformation, progressing from “following” to “running alongside,” and now to “leading.”